A new study presented at the Society of Interventional Radiology’s 37th Annual Scientific Meeting in San Francisco, USA, shows that a lower-dosage CT-guided lung biopsy protocol results in 66% average dose reduction with no difference in nodule size, or biopsy difficulty.
Delcath Systems has announced that Quintiles will provide a specialised team of medical science liaisons to support the launch of the hepatic Chemosat delivery system for the treatment of cancers in the liver in France, Germany, Italy, Netherlands, Spain, Ireland and the United Kingdom. In addition, it will provide medical communication to support patient advocacy, key opinion leader development, and field force materials.
Covidien has announced the launch of the HALO60 ablation catheter, the latest addition to the HALO family of catheters for the endoscopic treatment of Barrett’s esophagus.
SARAH (Sorafenib versus radioembolization in advanced hepatocellular carcinoma) is designed to directly compare the effectiveness of radioembolization with yttrium-90 resin microspheres (Sirtex) versus sorafenib (Bayer HealthCare Pharmaceuticals), a systemic therapy that is the current standard of care for patients with non-operable advanced hepatocellular carcinoma (HCC).
On 15 February, Delcath Systems and the European Institute of Oncology (Instituto Europeo di Oncologia – IEO) introduced the Delcath Hepatic Chemosat Delivery System to media at a press conference and discussed the status of the first European patients treated with the technology.
C. R. Bard, Inc. (NYSE: BCR) today announced that Christopher S. Holland has been named Senior Vice President and Chief Financial Officer, effective May 21, 2012. In this role, Mr. Holland will report directly to Timothy M. Ring, Chairman and Chief Executive Officer. BUSINESS WIRE.
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that preliminary data demonstrated the company’s EnligHTN™ renal denervation system was safe and effective for the treatment of resistant hypertension. The study demonstrated that on average patients with resistant hypertension experience a systolic blood pressure reduction of 28 points after 30 days.
St. Jude Medical, Inc. (NYSE:STJ ), a global medical device company, today announced CE Mark Approval and launch of its EnligHTN™ renal denervation system during EuroPCR. Renal denervation is a specialized ablation procedure that has been clinically proven to reduce blood pressure in patients with hypertension, or high blood pressure, that is resistant to medical therapy. Clinical data from the EnligHTN I trial about the safety and efficacy of the company’s renal denervation technology will be presented on Wednesday.
Boston Scientific Corporation (NYSE: BSX) announces CE Mark and European market launch of the Innova Self-Expanding Bare-Metal Stent System, which is designed to treat peripheral vascular lesions in arteries above the knee, specifically the superficial femoral artery (SFA) and proximal popliteal artery (PPA). The company plans to launch the product immediately in Europe and other CE Mark countries.
ReCor Medical, an emerging medical device company, announced today that it has completed enrollment in the REDUCE 15-patient pilot clinical study of its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation. PARADISE, which is CE-marked, is designed to treat patients with ‘resistant’ hypertension (“HTN”), a major risk factor for cardiovascular disease.
One-third of imaging tests performed to evaluate patients for possible pulmonary embolism may be unnecessary, a prospective observational study found. Among patients who had a CT scan or other imaging study as part of a work-up for pulmonary embolism, 32% (95% CI 31 to 34) of the tests would have been classified as "avoidable" according to a measure endorsed by the National Quality Forum, reported Christopher Kabrhel, MD, of Harvard University in Boston, and colleagues.
St. Jude Medical, Inc. (STJ), a global medical device company, today announced it has received U.S. Food and Drug Administration (FDA) clearance and will immediately launch the AMPLATZER™ Vascular Plug 4 (AVP 4) for use in transcatheter embolization procedures (minimally invasive procedures that involve the selective blocking of blood vessels) within the peripheral vasculature. Approximately 50,000 peripheral embolizations are performed each year in the United States.
To enable hospitals to keep pace with the latest technological advances and offer better patient care and improved workflow while containing costs, Toshiba America Medical Systems, Inc. announces the availability of VeloCT. This console upgrade includes new enhancements for patient safety, dose management and workflow for existing Aquilion™ 32, Aquilion 64 and Aquilion CX CT systems manufactured between 2006 and 2012.
Siemens Healthcare (SI) has announced that the Food and Drug Administration (FDA) has cleared the SOMATOM® Perspective – an advanced 128-slice computed tomography (CT) scanner engineered to drive efficiency and reduce costs.
Nordion has announced that organisers of the World Congress on Interventional Oncology (WCIO) 2012 hosted a live administration of the company s TheraSphere Yttrium-90 (Y-90) glass microsphere liver cancer treatment.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos